Intradermal Toxin for Oily Skin and Pores: The Evidence

Among the uses of botulinum toxin that have gained popularity in recent years, treating oily skin and enlarged pores is one of the most publicized and least solid from a scientific standpoint. The idea is seductive: inject small amounts superficially to reduce gland activity and "refine" the look of the skin. The problem is the distance between what is seen on social media and what is known with confidence.

This page offers a critical review at a general level. It names no products, presents no specific study figures and teaches no injection technique. The aim is to give the professional an honest reading of the evidence, to guide decision and consent, in line with the rules of their professional council.

What is the biological hypothesis?

The skin has sebaceous and sweat glands, and regulation of part of that activity involves cholinergic innervation. Botulinum toxin blocks the release of acetylcholine, and so it has been proposed as a possible modulator of glandular secretion and of the tone of the arrector pili muscles. The hypothesis is that, by reducing that activity, there would be less oiliness and less traction on the follicles, which would change the look of the pores.

This logic is plausible. In conditions such as hyperhidrosis, the use of toxin to reduce sweat is established. In the case of sebum, the connection is less direct: the sebaceous gland is regulated mainly by hormones and other mechanisms, and the role of cholinergic innervation is less clear. Therefore, what holds for sweat cannot be automatically carried over to sebum.

To understand the basics, see sebaceous gland and enlarged pores, as well as the page on microtoxin.

What does the literature allow us to say?

The body of publications on intradermal toxin for oiliness and pores tends to share similar features:

• Small samples and, often, no adequate control group.
• Heterogeneous measurement methods, such as visual scale ratings, sebum measurement devices and the rater's opinion.
• Short follow-up, which does not allow conclusions about real duration.
• Wide variation in technique, dilution and areas treated, which makes comparison difficult.
• Risk of publication bias and conflict of interest, common in aesthetics.

This does not mean the effect does not exist, but that the degree of certainty is low. To read critically, see levels of evidence in HOF, publication bias and conflict of interest in aesthetics and how to read a clinical trial of injectables.

How is the evidence organized?

A useful way to organize the reading is to separate what is plausible, what is observed and what is proven:

This distinction helps calibrate the message. It is legitimate to say "there is a hypothesis and reports of improvement in some patients." It is not legitimate to say "toxin shrinks pores" as an established fact.

Who could be a candidate?

The discussion becomes more reasonable when the patient has realistic expectations and alternatives have been considered. Some profiles that tend to come up:

• Persistent oily skin that did not respond to usual dermatologic care.
• Evident pores in the central face, associated with oiliness.
• A patient seeking a subtle improvement in texture who accepts that the effect is temporary and variable.

Before considering toxin, it is reasonable for the patient to have had a skin care routine assessment, treatment of active acne where present, and a review of habits and medications. Referral to a dermatologist is appropriate in cases of acne, rosacea or seborrheic dermatitis (see active acne and infection risk in HOF).

What are the risks?

Even in superficial use, toxin has risks that must be explained:

• Spread to underlying muscles, with unexpected weakening of expressions, especially in the forehead, cheeks and perioral area.
• Asymmetry, from uneven distribution or differences in response.
• Ecchymosis and local pain, more frequent with multiple punctures.
• Skin reactions, such as erythema, papules and, rarely, local infection.
• Frustrated expectation, which is an ethical risk when the promise exceeds the evidence.

Safety depends on training, anatomical knowledge and respect for limits. In areas with important expression muscles, wide distribution can lead to loss of naturalness. For the overview of complications, see complications with botulinum toxin.

How to align expectations?

The greatest ethical risk of this indication is the implicit promise. Terms such as "closed pores" or "porcelain skin" create an expectation that science does not support. Prefer cautious language: "there may be a subtle improvement in oiliness and skin appearance in some patients, with no guarantee, and the effect is temporary."

In promotional material, avoid before-and-afters that suggest pore transformation, and follow the rules of your council and CONAR (Brazil's advertising self-regulation council). The page on what can be advertised gives the general reasoning.

How does it compare with other options?

For oiliness and pores, there are non-injectable strategies and others using technology or topical actives, each with its own evidence and risk profile. Rather than comparing, it is more useful to think in sequence: first routine care and treating causes, then, if needed, procedures such as microneedling, fractional laser or skin booster, each with its own indications. Intradermal toxin comes in, when it does, as an additional option, not as a substitute.

How to document?

The record should include the concern, the exam, the explanation of off-label use, the alternatives, the specific consent and the follow-up plan. If the patient wants a result you consider unattainable, record the conversation and the refusal. The follow-up visit should assess not only the skin but also facial expression and any unwanted effects.